RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Open accessThe DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Abstract
DIAGNOSIS OF DIABETES RECOMMENDATIONSTable: No title available.Table: No title available.NOTE Estimation of HbA1c should be performed using NGSP standardized method. Capillar y glucose estimation methods are not recommended for diagnosis Venous plasma is used for estimation of glucose Plasma must be separated soon after collection because the blood glucose levels drop by 5%–8% hourly if whole blood is stored at room temperature. For more details on glucose estimation visit: http://www.ncbi.nlm.nih.gov/books/NBK248/ *FPG is defined as glucose estimated after no caloric intake for at least 8–12 hours. **Using a method that is National Glycohaemoglobin Standardization Program (NGSP) certified. For more on HbA1c and NGSP, please visit http://www.ngsp.org/index.asp BACKGROUND The diagnostic criteria of diabetes have been constantly evolving. Both type 1 and type 2 Diabetes mellitus (DM) are diagnosed based on the plasma glucose criteria, either the fasting plasma glucose (FPG) levels or the 2-h plasma post-prandial glucose (2-h PPG) levels during a 75-g oral glucose tolerance test (OGTT), or the newer glycosylated haemoglobin (HbA1c) criteria which reflects the average plasma glucose concentration over the previous 8–12 weeks.[12] The International Expert Committee Report recommend a cut-point of ≥6.5% for HbA1c for diagnosing diabetes as an alternative to fasting plasma glucose (FPG ≥7.0 mmol/L).[3] HbA1c testing has some substantial advantages over FPG and OGTT, such as convenience, pre-analytical stability, and less day-to-day fluctuations due to stress and illness.[3] Additionally, HbA1c has been recognized as marker to assess secondary vascular complications due to metabolic derailments in susceptible individuals.[245] However, given ethnic differences in sensitivity and specificity of HbA1c population-specific cut-offs might be necessary.[67] Moreover, measuring HbA1c is expensive as compared to FPG assessments and standardization of measurement techniques and laboratories are poorly practiced across the country.[8] Also, in several countries including India, HbA1c demonstrated inadequate predictive accuracy in the diagnosis of diabetes, there is no consensus on a suitable cut-off point of HbA1c for diagnosis of diabetes in this high-risk population.[9] In lieu of this, the panel expressed concerns on using HbA1c as sole criteria for diagnosis of diabetes particularly in resource constraint settings. Therefore, a combination of HbA1cand FPG would improve the identification of individuals with diabetes mellitus and prediabetes in limited resource settings like India. CONSIDERATIONS The decision about setting diagnostic thresholds values was based on the cost-effective strategies for diagnosing diabetes that were reviewed in Indian context. RATIONALE AND EVIDENCE Glycosylated haemoglobin cut off for diagnosis of diabetes in Indian patients The RSSDI expert panel suggests [WHITE SMALL SQUAREHbA1c ≥6.5% as optimal level for diagnosis of diabetes in Indian patients [WHITE SMALL SQUAREHbA1c cannot be used as 'sole' measurement for diagnosis of diabetes in Indian settings. These recommendations are based on the Indian evidences A recent study conducted in Singapore residents of Chinese, Malay and Indian race to assess the performance of HbA1c as a screening test in Asian populations suggested that HbA1c is an appropriate alternative to FPG as a first-step screening test, and a combination of HbA1c with a cut-off of ≥6.1% and FPG level ≥100 mg/dL would improve detection in patients with diabetes.[6] A study to assess the diagnostic accuracy and optimal HbA1c cutoffs for diabetes and prediabetes among high-risk south Indians suggested that HbA1c ≥6.5% can be defined as a cut-off for diabetes and HbA1c ≥5.9% is optimal for prediabetes diagnosis and value <5.6% excludes prediabetes/diabetes status.[8] Data from a community based randomized cross sectional study in urban Chandigarh suggest that HbA1c cut point of 6.5% has optimal specificity of 88%, while cut off point of 7.0% has sensitivity of 92% for diagnosis of diabetes.[10] The results of the Chennai Urban Rural Epidemiology Study (CURES) demonstrated 88.0% sensitivity and 87.9% specificity for detection of diabetes when HbA1c cut off point is 6.1% (based on 2-h post load plasma glucose) and 93.3% sensitivity and 92.3% specificity when HbA1c cut off point is 6.4% (when diabetes was defined as FPG ≥7.0 mmol/l).[11] However, panel emphasized that HbA1c can be used in settings where an appropriate standardized method is available. IMPLEMENTATION Individuals should be educated on the advantages of early diagnosis and should be encouraged to participate in community screening programs for diagnosis. PREVENTION RECOMMENDATIONSTable: No title available.Table: No title available.BACKGROUND Chronic hyperglycaemia is associated with significantly higher risk of developing diabetes related micro-and macrovascular complications. Early detection of diabetes/prediabetes throu
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Lee, I.-M., Shiroma, E. J., Lobelo, F., Puska, P., Blair, S. N., & Katzmarzyk, P. T. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61031-9 · Cited by 8,215
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“in terms of reduced diabetes-related endpoints, diabetesrelated deaths, and all-cause mortality.[169] Along with”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 72×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119 · cited 1×
“resulted in lower mortality than a target of 81 to 108 mg/dL [Table 32].[857] Although the Leuven trial was associated with”
BackgroundImpotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074 · cited 1×
“Diabetes ensued vasculopathy and neuropathy has been associated with dysfuntion of normal sexual function leading to psychosocial disruption and decreased quality of life in both men and women.[660-662] Sexual dysfunction (SD) in diabetics is a neglected aspect in India, primarily due to minimal communication time bet…”
BackgroundGlobal prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Diabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 1×
“Tricyclic antidepressants, venlafaxine, carbamazepine, and topical capsaicin, although not approved for the treatment of painful diabetic neuropathy, may be effective and considered for the treatment.[433-436] • Capsaicin has been used with some success in the treatment of patients with PDN.”
BackgroundThe Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926 · cited 1×
“Prevalence of clinically significant depression, anxiety, eating behaviour disorder are considerably more common in patients with diabetes than in those without the disease.[958-960] • The findings from a systematic review and metaanalysis conducted on 248 observational studies demonstrated that almost one in four adu…”
ResultInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 70×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
InfluentialDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 4×
“It is estimated that 15% of TB cases globally could be attributed to diabetes and 40% of these cases are from India and China.”
BackgroundInfluentialDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
O'Donnell, M. J., Chin, S. L., Rangarajan, S., Xavier, D., Liu, L., Zhang, H., Rao-Melacini, P., Zhang, X., Pais, P., Agapay, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30506-2 · Cited by 2,296
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“At 24 months, 64% of those who had lost more than 10 kg, were still in remission.[630,631] • The findings of the randomized controlled PREVIEW lifestyle intervention study reported that the total physical activity accounts for greater variance in IR and some related cardiometabolic risk factors as compared with modera…”
BackgroundInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationHyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Brethauer, S. A., Navaneethan, S. D., Aminian, A., Pothier, C. E., Kim, E. S. H., Nissen, S. E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401329 · Cited by 1,901
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Self-Management Education for Adults With Type 2 Diabetes
Norris, S. L., Lau, J., Smith, S. J., Schmid, C. H., & Engelgau, M. M. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1159 · Cited by 1,750
Mills, J. L., Conte, M. S., Armstrong, D. G., Pomposelli, F. B., Schanzer, A., Sidawy, A. N., & Andros, G. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.08.003 · Cited by 1,718
Quantity and Quality of Sleep and Incidence of Type 2 Diabetes
Cappuccio, F. P., D'Elia, L., Strazzullo, P., & Miller, M. A. (2010) · Diabetes Care · doi:10.2337/dc09-1124 · Cited by 1,670
McKeigue, P. M., Shah, B., & Marmot, M. G. (1991) · The Lancet · doi:10.1016/0140-6736(91)91164-p · Cited by 1,618
Depression and Type 2 Diabetes Over the Lifespan
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008) · Diabetes Care · doi:10.2337/dc08-0985 · Cited by 1,558
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 69×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
ResultInfluentialDepression and Diabetes: Impact of Depressive Symptoms on Adherence, Function, and Costs
Ciechanowski, P. S., Katon, W. J., & Russo, J. E. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3278 · Cited by 1,465 · cited 1×
“[941] The psychological and social issues such as stress, anxiety, depression, eating disorders, cognitive dysfunction, or other psychological disorders are associated with poor self-care, increased mortality, functional impairment, increased healthcare cost, loss of productivity, and reduced quality of life.[942-945]…”
BackgroundMonnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016) · Biomarker Insights · doi:10.4137/bmi.s38440 · Cited by 1,381
Effects of Dietary Fiber and Its Components on Metabolic Health
Lattimer, J. M., & Haub, M. D. (2010) · Nutrients · doi:10.3390/nu2121266 · Cited by 1,333 · cited 1×
“Fibrerich foods contain complex carbohydrates that are resistant to digestion and thereby reduce glucose absorption and insulin secretion.[79,138,139] • In overweight or obese patients with T2DM, a low glycaemic-index, high-fibre diet significantly (p<0.”
BackgroundStress and cardiovascular disease
Steptoe, A., & Kivimäki, M. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.45 · Cited by 1,321
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266
Effects of aspirin for primary prevention in persons with diabetes mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804988 · Cited by 1,200 · cited 1×
“However, these preventive benefits were counterbalanced with major bleeding hazards.[560] Furthermore, a metaanalysis demonstrated 35% reduction in MI among men (RR: 0.”
BackgroundEffect of Clinical Decision-Support Systems: A Systematic Review
Bright, T. J., Wong, A., Dhurjati, R., Bristow, E., Bastian, L., Coeytaux, R. R., Samsa, G., Hasselblad, V., Williams, J. W., Musty, M. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-1-201207030-00450 · Cited by 1,200
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162
Relationship of Depression and Diabetes Self-Care, Medication Adherence, and Preventive Care
Lin, E. H. B., Katon, W., Von Korff, M., Rutter, C., Simon, G. E., Oliver, M., Ciechanowski, P., Ludman, E. J., Bush, T., & Young, B. (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2154 · Cited by 1,146 · cited 1×
“[961] • Poor psychological functioning can seriously interfere with daily diabetes self-management, with subsequent poor medical outcomes and high costs.[962,963]”
BackgroundPioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Dehghan, M., Mente, A., Zhang, X., Swaminathan, S., Li, W., Mohan, V., Iqbal, R., Kumar, R., Wentzel-Viljoen, E., Rosengren, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32252-3 · Cited by 1,101
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · cited 2×
“• QRISK3 Risk Score[541,542] • UKPDS Risk Engine.”
BackgroundRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041 · cited 1×
“Such strategies help in setting up realistic goals, guide patients in identifying stimulus that lead to excessive nutrient intake and eliminate them accordingly.[621] • Bodyweight has been shown to be inversely associated with physical activity.”
BackgroundLean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017 · cited 1×
“At 24 months, 64% of those who had lost more than 10 kg, were still in remission.[630,631] • The findings of the randomized controlled PREVIEW lifestyle intervention study reported that the total physical activity accounts for greater variance in IR and some related cardiometabolic risk factors as compared with modera…”
BackgroundChrvala, C. A., Sherr, D., & Lipman, R. D. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2015.11.003 · Cited by 914
Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies
Shan, Z., Ma, H., Xie, M., Yan, P., Guo, Y., Bao, W., Rong, Y., Jackson, C. L., Hu, F. B., & Liu, L. (2015) · Diabetes Care · doi:10.2337/dc14-2073 · Cited by 902
The role of exercise and physical activity in weight loss and maintenance
Swift, D. L., Johannsen, N. M., Lavie, C. J., Earnest, C. P., & Church, T. S. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.09.012 · Cited by 855
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Type 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824 · cited 70×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundResultInfluentialThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“Limiting side effects of these agents are nausea and vomiting, particularly early in the course of treatment.[235] • In combination with basal insulin they have proved to be extremely useful option for intensification because of complimentary action (IDegLira, Lixilan).”
BackgroundEgede, L. E., Zheng, D., & Simpson, K. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.464 · Cited by 816 · cited 1×
“[961] • Poor psychological functioning can seriously interfere with daily diabetes self-management, with subsequent poor medical outcomes and high costs.[962,963]”
BackgroundIntroduction: Standards of Medical Care in Diabetes—2022
American Diabetes Association (2022) · Diabetes Care · doi:10.2337/dc22-sint · Cited by 807
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Augustin, L. S. A., Kendall, C. W. C., Jenkins, D. J. A., Willett, W. C., Astrup, A., Barclay, A. W., Björck, I., Brand-Miller, J. C., Brighenti, F., Buyken, A. E., et al. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.05.005 · Cited by 707
5. Lifestyle Management:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s005 · Cited by 700
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684 · cited 2×
“[205,207,237,276-280] • In patients with heart failure and CKD, SGLT2i or GLP-1 agon is t s may be prefe r red u n less contraindicated.[205,207,278,281,282] • Pioglitazone has been shown in few studies to reduce CVD risk,[184,186] however, pioglitazone should not be used in patients with subclinical heart failure[280…”
BackgroundLess-Tight versus Tight Control of Hypertension in Pregnancy
Magee, L. A., von Dadelszen, P., Rey, E., Ross, S., Asztalos, E., Murphy, K. E., Menzies, J., Sanchez, J., Singer, J., Gafni, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404595 · Cited by 672
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667 · cited 1×
“Initiation of insulin therapy [Figures 3 and 4] • As initial therapy, unless the patient is passing through an acute medical, surgical or obstetric crisis, or in metabolic decompensation, premixed or basal insulin is typically initiated [Tables 5 and 6].[219,221,232,233] General concept is to first correct the fasting…”
BackgroundLawrence, J. M., Contreras, R., Chen, W., & Sacks, D. A. (2008) · Diabetes Care · doi:10.2337/dc07-2345 · Cited by 658
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Tricco, A. C., Ivers, N. M., Grimshaw, J. M., Moher, D., Turner, L., Galipeau, J., Halperin, I., Vachon, B., Ramsay, T., Manns, B., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60480-2 · Cited by 652 · cited 1×
“An organized, systematic approach in diabetes self-management and a continued support from a trained multidisciplinary diabetes care team are thus highly crucial for achieving optimal outcomes.[780,781] Many solutions have been identified or are being employed to achieve this such as redesigning the organization of th…”
MethodPerkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626 · cited 69×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundInfluentialRaz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614 · cited 1×
“Additionally, homeostasis model assessment of beta cell function index, fasting proinsulin-insulin ratio which are the markers of insulin secretion, and beta cell function were also improved significantly.[193] The overall incidence of adverse events with sitagliptin is comparable to other OADs when used as monotherap…”
ResultBennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609 · cited 1×
“1%.[239] Moreover, current National Insulin Summit (NIS) consensus from India report that all oral antidiabetic agents and GLP-1 agonists can reduce HbA1c to a range of 0.”
BackgroundInternational Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 1×
“[423-425] Moreover, a recent Cochrane collaboration review including data from eight studies and 2728 participants report that both 60 mg and 120 mg daily doses of duloxetine were efficacious, but lower doses were not associated with improvement in the PDN management.[426] • Tapentadol, an opioid analgesic, may act vi…”
BackgroundLustman, P. J., Griffith, L. S., Freedland, K. E., Kissel, S. S., & Clouse, R. E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-8-199810150-00005 · Cited by 562
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Increased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet
Saper, R. B. (2008) · JAMA · doi:10.1001/jama.300.8.915 · Cited by 533
Ismail, K., Winkley, K., & Rabe-Hesketh, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16202-8 · Cited by 531
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
State of the art paper Sulfonylureas and their use in clinical practice
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.53304 · Cited by 514
Miller, K. M., Beck, R. W., Bergenstal, R. M., Goland, R. S., Haller, M. J., McGill, J. B., Rodriguez, H., Simmons, J. H., Hirsch, I. B., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1770 · Cited by 505
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Nutrition Transition and the Global Diabetes Epidemic
Popkin, B. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0631-4 · Cited by 479 · cited 1×
“[87-89] MNT is a systematic approach to optimize dietary intake in order to achieve metabolic control and maximize favourable treatment outcomes in T2DM.”
BackgroundEffect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Managing preexisting diabetes for pregnancy
Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., et al. (2008) · Diabetes Care · doi:10.2337/dc08-9020 · Cited by 476
A history of blood glucose meters and their role in self-monitoring of diabetes mellitus
Clarke, S. F., & Foster, J. R. (2012) · British Journal of Biomedical Science · doi:10.1080/09674845.2012.12002443 · Cited by 456
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435 · cited 1×
“Therefore, treatments that target factors beyond glycaemic control, such cardiovascular risks, weight management, along with improvements in quality of life have been introduced.[163] Several guidelines/recommendations provide treatment algorithms on ways in which glucoselowering agents can be used either alone or in…”
BackgroundPolonsky, W. H., Fisher, L., Schikman, C. H., Hinnen, D. A., Parkin, C. G., Jelsovsky, Z., Petersen, B., Schweitzer, M., & Wagner, R. S. (2011) · Diabetes Care · doi:10.2337/dc10-1732 · Cited by 429 · cited 2×
“SMBG is currently the optimal method for assessing plasma glucose levels and evidence suggests that structured SMBG followed by therapeutic interventions result in greater HbA1c reduction in individuals with T2DM compared with programs without structured SMBG.[332-334] Therefore, the panel suggest to include SMBG with…”
BackgroundMethodCanagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 1×
“8]).[206] The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk.”
MethodKhaledi, M., Haghighatdoost, F., Feizi, A., & Aminorroaya, A. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01295-9 · Cited by 359 · cited 1×
“professional with elderly.[961] • Poor psychological functioning can seriously interfere with daily diabetes self-management, with subsequent poor medical outcomes and high costs.”
BackgroundWhat is the best predictor of future type 2 diabetes
Abdul-Ghani, M. A., Williams, K., DeFronzo, R. A., & Stern, M. (2007) · Diabetes Care · doi:10.2337/dc06-1331 · Cited by 355
Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351 · cited 69×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundInfluentialGulliksson, M., Burell, G., Vessby, B., Lundin, L., Toss, H., & Svärdsudd, K. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.510 · Cited by 349 · cited 1×
“28) than the reference group after adjustment for other outcome-affecting variables during a mean 94 months of follow-up period.[557] Nonetheless, a recent Cochrane review did not find such associations of CVD events with the psychological interventions in CHD patients.”
BackgroundUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Misra, A., Vikram, N. K., Gupta, R., Pandey, R. M., Wasir, J. S., & Gupta, V. P. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803111 · Cited by 332
Ramachandran, A., Snehalatha, C., Ram, J., Selvam, S., Simon, M., Nanditha, A., Shetty, A. S., Godsland, I. F., Chaturvedi, N., Majeed, A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70067-6 · Cited by 330
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes
Hussain, T. A., Mathew, T. C., Dashti, A. A., Asfar, S., Al-Zaid, N., & Dashti, H. M. (2012) · Nutrition · doi:10.1016/j.nut.2012.01.016 · Cited by 329 · cited 1×
“[122] • In a 24-week interventional study, a low-carbohydrate ketogenic diet in patients with T2DM favourably improved body weight, glycaemic and lipid profiles in patients with T2DM as compared with patients on a low calorie diet.[123]”
Background8. Cardiovascular Disease and Risk Management
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s011 · Cited by 329
Heisler, M., Piette, J. D., Spencer, M., Kieffer, E., & Vijan, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.816 · Cited by 326
Holman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30309-1 · Cited by 323 · cited 1×
“the longer term by delaying the onset of T2DM in the high-risk population.[323]”
BackgroundLee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320 · cited 1×
“first choice drug with some evidence for weight loss.[635,636] The DPP and Indian Diabetes Prevention Program (IDPP) trial report that metformin and lifestyle intervention greatly reduce the risk of T2DM in overweight or obese patients.”
BackgroundPCSK9 inhibitors: A new era of lipid lowering therapy
Chaudhary, R., Garg, J., Shah, N., & Sumner, A. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.76 · Cited by 299
Thomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000881 · Cited by 298 · cited 1×
“stroke event, albeit with greater adverse effects.[350,585,586]”
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042007 · Cited by 291
TODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2393 · Cited by 288
Diabetes self-management education core outcomes measures
Mulcahy, K., Maryniuk, M., Peeples, M., Peyrot, M., Tomky, D., Weaver, T., & Yarborough, P. (2003) · The Diabetes Educator · doi:10.1177/014572170302900509 · Cited by 273 · cited 1×
“[702,909] It is guided by evidence-based standards while incorporating needs, goals and life-experiences of the patients with diabetes.[910] The 2019 Standards of Medical Care in Diabetes recommends that people living with diabetes should be actively engaged in education, self-management, and treatment planning with t…”
BackgroundInnes, K. E., & Vincent, H. K. (2007) · Evidence-Based Complementary and Alternative Medicine · doi:10.1093/ecam/nel103 · Cited by 268 · cited 2×
“However, there is inadequate clinical evidence showing the benefits of yoga for glycemic control and therefore, it cannot substitute physical activity completely.[969,984,985] A randomized controlled study conducted in North India showed a significant improvement in the quality of life in the intervention group practi…”
BackgroundREDEEM: A pragmatic trial to reduce diabetes distress
Fisher, L., Hessler, D., Glasgow, R. E., Arean, P. A., Masharani, U., Naranjo, D., & Strycker, L. A. (2013) · Diabetes Care · doi:10.2337/dc12-2493 · Cited by 266 · cited 1×
“Solution • Collaborative care interventions and a team approach for diabetes management have demonstrated efficacy in selfmanagement with improved psychosocial outcomes.[964,965] • A systematic review and meta-analysis has shown that, overall, psychological interventions are effective in improving glycaemic control in…”
BackgroundSaslow, L. R., Mason, A. E., Kim, S., Goldman, V., Ploutz-Snyder, R., Bayandorian, H., Daubenmier, J., Hecht, F. M., & Moskowitz, J. T. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.5806 · Cited by 265
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265
(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Larsen, M. L., Hørder, M., & Mogensen, E. F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010113231503 · Cited by 257
Hypoglycemia: The neglected complication
Kalra, S., Mukherjee, J. J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A. K., & Ramachandran, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117219 · Cited by 255
Self-citationPeters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Trials
Innes, K. E., & Selfe, T. K. (2016) · Journal of Diabetes Research · doi:10.1155/2016/6979370 · Cited by 248 · cited 1×
“[552] Furthermore, evidence suggests that yoga also helps in reducing the blood glucose levels,[553-555] lipid levels,[553,554] body weight, and BP[554] in patients with T2DM.”
BackgroundSaslow, L. R., Daubenmier, J. J., Moskowitz, J. T., Kim, S., Murphy, E. J., Phinney, S. D., Ploutz-Snyder, R., Goldman, V., Cox, R. M., Mason, A. E., et al. (2017) · Nutrition & Diabetes · doi:10.1038/s41387-017-0006-9 · Cited by 241 · cited 1×
“01) than participants on moderate-carbohydrate, calorie-restricted, low-fat diet.[122] • In a 24-week interventional study, a low-carbohydrate ketogenic diet in patients with T2DM favourably improved body weight, glycaemic and lipid profiles in patients with T2DM as compared with patients on a low calorie diet.”
BackgroundKautiainen, S., Koivusilta, L., Lintonen, T., Virtanen, S. M., & Rimpelä, A. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802994 · Cited by 238
Reznik, Y., Cohen, O., Aronson, R., Conget, I., Runzis, S., Castaneda, J., & Lee, S. W. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61037-0 · Cited by 233
Sackner-Bernstein, J., Kanter, D., & Kaul, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139817 · Cited by 220
Telemedicine Application in the Care of Diabetes Patients: Systematic Review and Meta-Analysis
Marcolino, M. S., Maia, J. X., Alkmim, M. B. M., Boersma, E., & Ribeiro, A. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079246 · Cited by 215 · cited 1×
“In populations with limited access to care, telemedicine effectively improves the overall disease outcomes.[787-791] Diabetes Tele Management System, DTMS®, a telemedicine-based diabetes care implemented at a diabetes care hospital in South India since the 1990s, is now well”
BackgroundMarx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212
Lee, S. W. H., Chan, C. K. Y., Chua, S. S., & Chaiyakunapruk, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-12987-z · Cited by 200 · cited 1×
“In populations with limited access to care, telemedicine effectively improves the overall disease outcomes.[787-791] Diabetes Tele Management System, DTMS®, a telemedicine-based diabetes care implemented at a diabetes care hospital in South India since the 1990s, is now well”
BackgroundAzoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195 · cited 1×
“Further, sulfonylureas and meglitinides increase the risk of myocardial ischemic injury and may be associated with increased risk of cardiovascular events and mortality.[808] SGLT-2 inhibitors are associated with high risks for DKA and volume depletion.”
BackgroundChristensen, P., Meinert Larsen, T., Westerterp‐Plantenga, M., Macdonald, I., Martinez, J. A., Handjiev, S., Poppitt, S., Hansen, S., Ritz, C., Astrup, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13466 · Cited by 188 · cited 1×
“[632,633] Fixed low-energy diet has been shown to induce an overall 11% weight loss and showed significant improvements in insulin resistance; men appeared to benefit more than women.[634] • Therefore the panel suggests that prescribing a combination of aerobic and resistance training exercises in individuals with T2D…”
BackgroundWing, R. R., Rosen, R. C., Fava, J. L., Bahnson, J., Brancati, F., Gendrano, I. N. C., Kitabchi, A., Schneider, S. H., & Wadden, T. A. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01458.x · Cited by 180
7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Lean diabetes mellitus: An emerging entity in the era of obesity
George, A. M., Jacob, A. G., & Fogelfeld, L. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.613 · Cited by 177
The Look AHEAD Trial: a review and discussion of its outcomes
Pi-Sunyer, X. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0099-x · Cited by 176 · cited 1×
“At 11 years, participants benefited from the regimented diet and had an average weight loss of 5% along with substantial improvements in HbA1c levels, blood pressure, lipid profile and overall fitness and well-being.[96] In a year-long prospective randomized study from India, individuals with T2DM, randomized to MNT,…”
BackgroundKalinchenko, S. Y., Kozlov, G. I., Gontcharov, N. P., & Katsiya, G. V. (2003) · The Aging Male · doi:10.1080/tam.6.2.94.99 · Cited by 173
Disordered Eating Behavior in Individuals With Diabetes
Young-Hyman, D. L., & Davis, C. L. (2010) · Diabetes Care · doi:10.2337/dc08-1077 · Cited by 172
Radhika, G., Van Dam, R. M., Sudha, V., Ganesan, A., & Mohan, V. (2009) · Metabolism · doi:10.1016/j.metabol.2009.01.008 · Cited by 171
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163 · cited 2×
“[637] Use of GLP-1receptor agonists,[254] SGLT-2 inhibitors,[255,638] and to some extents DPP-4 inhibitors[257,258] have been shown to induce weight loss and should be considered as add-on to metformin in obese T2DM patients.”
BackgroundDraeger, K., Wernicke-Panten, K., Lomp, H.-J., Schüler, E., & Roßkamp, R. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979830 · Cited by 161
The Elevated Susceptibility to Diabetes in India: An Evolutionary Perspective
Wells, J. C. K., Pomeroy, E., Walimbe, S. R., Popkin, B. M., & Yajnik, C. S. (2016) · Frontiers in Public Health · doi:10.3389/fpubh.2016.00145 · Cited by 155 · cited 69×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundInfluentialRados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0128 · Cited by 139
Cavagnolli, G., Pimentel, A. L., Freitas, P. A. C., Gross, J. L., & Camargo, J. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171315 · Cited by 138 · cited 7×
“[31] The predictive value of HbA1c for T2DM depends on various factors such as ethnicity, age, and presence of iron deficiency anaemia (IDA).[32-35] In a cohort study on individuals from Swedish and Middle-East ancestry, HbA1 ≥48 mmol/mol had a predictive sensitivity of 31% and 25%, respectively, for T2DM.”
BackgroundInfluentialFranciosi, M., Lucisano, G., Pellegrini, F., Cantarello, A., Consoli, A., Cucco, L., Ghidelli, R., Sartore, G., Sciangula, L., Nicolucci, A., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03268.x · Cited by 137
Heitkemper, E. M., Mamykina, L., Travers, J., & Smaldone, A. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx025 · Cited by 130 · cited 1×
“In populations with limited access to care, telemedicine effectively improves the overall disease outcomes.[787-791] Diabetes Tele Management System, DTMS®, a telemedicine-based diabetes care implemented at a diabetes care hospital in South India since the 1990s, is now well”
BackgroundA1C Cut Points to Define Various Glucose Intolerance Groups in Asian Indians
Mohan, V., Vijayachandrika, V., Gokulakrishnan, K., Anjana, R. M., Ganesan, A., Weber, M. B., & Narayan, K. M. V. (2010) · Diabetes Care · doi:10.2337/dc09-1694 · Cited by 118 · cited 2×
“[13] Evidence that influenza can trigger coronary complications, when taken in the context of diabetes subjects, gains more significance since the risk for CVD is already 2-to 4-fold higher in this sub group.[11,14] ▫ Retroviral infections: Cirrhosis of liver in diabetes patients results in higher incidence of glucose…”
BackgroundDe Natale, C., Annuzzi, G., Bozzetto, L., Mazzarella, R., Costabile, G., Ciano, O., Riccardi, G., & Rivellese, A. A. (2009) · Diabetes Care · doi:10.2337/dc09-0266 · Cited by 114 · cited 1×
“[100,101] Recent studies support the implementation of a long-term high-carbohydrate high-fibre diet in promoting weight loss, improving glycaemic control, and lowering CV risk.[102-105] High carbohydrate diets should comprise large amounts of unrefined carbohydrate and fibre such as legumes, whole grains, unprocessed…”
BackgroundAcarbose in the treatment of elderly patients with type 2 diabetes
Josse, R. G., Chiasson, J.-L., Ryan, E. A., Lau, D. C. W., Ross, S. A., Yale, J.-F., Leiter, L. A., Maheux, P., Tessier, D., Wolever, T. M. S., et al. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00176-6 · Cited by 110 · cited 69×
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundInfluentialSpence, J. D., Viscoli, C. M., Inzucchi, S. E., Dearborn-Tomazos, J., Ford, G. A., Gorman, M., Furie, K. L., Lovejoy, A. M., Young, L. H., Kernan, W. N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0079 · Cited by 109
Cedernaes, J., Schiöth, H. B., & Benedict, C. (2015) · Diabetes · doi:10.2337/db14-1475 · Cited by 103 · cited 1×
“Optimal sleep (7–8 h/night) has been shown to maintain metabolic health, aid in weight loss, and increase insulin sensitivity, while short duration (<5–6 h) or longer duration (>8–9 h) of sleep was associated with increased risk of diabetes.[72,73] Similar results were observed in a systematic review and meta-analysis…”
ResultEffects of yoga in adults with type 2 diabetes mellitus: A meta-analysis
Cui, J., Yan, J., Yan, L., Pan, L., Le, J., & Guo, Y. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12548 · Cited by 103
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
Self-citationBohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32328-6 · Cited by 94
Brown, T., Smith, S., Bhopal, R., Kasim, A., & Summerbell, C. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120100566 · Cited by 91 · cited 1×
“[621] • Bodyweight has been shown to be inversely associated with physical activity.[622] Patients with low physical activity have 3-fold greater risk of major weight gain in men and almost a 4-fold in women.”
BackgroundProfessional Practice Committee: Standards of Medical Care in Diabetes—2018
(2018) · Diabetes Care · doi:10.2337/dc18-sppc01 · Cited by 84
Off-label drugs for weight management
Hendricks, E. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s95299 · Cited by 82 · cited 1×
“first choice drug with some evidence for weight loss.[635,636] The DPP and Indian Diabetes Prevention Program (IDPP) trial report that metformin and lifestyle intervention greatly reduce the risk of T2DM in overweight or obese patients.”
BackgroundLee, P., Chang, A., Blaum, C., Vlajnic, A., Gao, L., & Halter, J. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03773.x · Cited by 50
Kempf, K., Kruse, J., & Martin, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0116 · Cited by 48
Silva, D. D. R., & Bosco, A. A. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-7-2 · Cited by 35
Success with lifestyle monotherapy in youth with new-onset type 2 diabetes
Wittmeier, K. D., Wicklow, B. A., Sellers, E. A., Griffith, A. T., Dean, H. J., & McGavock, J. M. (2012) · Paediatrics & Child Health · doi:10.1093/pch/17.3.129 · Cited by 32 · cited 1×
“Although lifestyle modification is the most commonly used intervention in adolescents with type 2 diabetes, less than 20% achieve or maintain adequate glycaemic control with lifestyle intervention alone.[877] Aerobic activity, alone or in combination with diet, can reduce systolic blood pressure, reduce total choleste…”
BackgroundmDiabetes initiative using text messages to improve lifestyle and health-seeking behaviour in India
Ramachandran, A., Kumar, R., Nanditha, A., Raghavan, A., Snehalatha, C., Krishnamoorthy, S., Joshi, P., & Tesfaye, F. (2018) · BMJ Innovations · doi:10.1136/bmjinnov-2017-000265 · Cited by 22 · cited 1×
“The WHO has recommended the use of such strategies for large scale programmes.[76,77] ▫ Dietary interventions such as high-carbohydrate, lowfat diet,[78] fibre-rich,[79] and protein-rich diet[80,81] were found to have definite role in prevention of diabetes.”
MethodRoy, M. K., Kuriakose, A. S., Varma, S. K., Jacob, L. A., & Beegum, N. J. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.07.003 · Cited by 19 · cited 1×
“[417-419] • Both duloxetine and pregabalin are effective; however, a significant improvement in QoL of patients was obtained by duloxetine with comparatively mild increase in the price.[420]”
Background
Cited by
Evaluation of the performance and usability of a novel continuous glucose monitoring system
Yan, L., Li, Q., Guan, Q., Han, M., Zhao, Y., Fang, J., & Zhao, J. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01112-0 · Cited by 13
Metadata
- Authors
- Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2020
- Volume
- 24
- Issue
- 1
- Pages
- 1
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W3023689184
- Cited by
- 167
- References
- 188
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.